



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 12 November 2025

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai – 400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., WEDNESDAY, NOVEMBER 12, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 51 (Part A and Part B of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“**SEBI Listing Regulations**”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., Wednesday, November 12, 2025, inter alia, duly approved and took on record the:

- Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 20, 2025.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with the limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications).
 - Details as per Regulation 52(4) of SEBI Listing Regulations.
- Re-appointment of Mr. Krishnakumar Vaidyanathan as Whole Time Director of the Company

Based on the recommendation of the Nomination & Remuneration Committee, the Board have considered and recommended to the members for their approval the re-appointment of Mr. Krishnakumar Vaidyanathan, as Whole Time Director of the Company, for a period of 5 (Five) years commencing from September 01, 2026, till August 31, 2031.

The details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as “**Annexure 1**”.

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Consumer Services Leadership Award, India



Business today/YES bank
Excellence Awards-2013



➤ **Re-appointment of Ms. Kalpana Unadkat as an Independent Director of the Company**

Based on the recommendation of the Nomination & Remuneration Committee, the Board have considered and recommended to the members for their approval the re-appointment of Ms. Kalpana Unadkat, as an Independent Director of the Company, for a period of 5 (Five) years commencing from January 05, 2026, till January 04, 2031.

The details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as “Annexure 1”.

The meeting of the Board of Directors commenced at 12:00 P.M. and concluded at 01:30 P.M.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Eris Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and joint venture (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 30 September 2025 and the consolidated year to date results for the period 01 April 2025 to 30 September 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the financial results of 6 subsidiaries included in the Statement, whose financial information reflects total assets of ₹ 1,066.77 Crores as at 30 September 2025, and total revenues of ₹ 142.84 Crores and ₹ 261.49 Crores, total net profit after tax of ₹ 52.13 Crores and ₹ 77.18 Crores, total comprehensive income of ₹ 52.08 Crores and ₹ 77.08 Crores, for the quarter and six-month period ended on 30 September 2025, respectively, and cash flows (net) of ₹ (11.94) Crores for the period ended 30 September 2025, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.28 Crores and ₹ 1.17 Crores and total comprehensive income of ₹ 0.28 Crores and ₹ 1.17 Crores, for the quarter and six-month period ended on 30 September 2025, respectively, as considered in the Statement, in respect of joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 30 September 2024 and audit of consolidated financial results for the quarter and year ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified conclusion vide their review report dated 25 October 2024 and unmodified opinion vide their audit report dated 19 May 2025, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013


Ashish Gupta
Partner
Membership No. 504662
UDIN: 25504662BM00IF4054

Place: Mumbai
Date: 12 November 2025



Walker Chandiook & Co LLP

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

List of entities included in the Statement

Holding Company

Sr. No.	Name of entity
1	Eris Lifesciences Limited

Subsidiaries

Sr. No.	Name of entities
1	Eris Therapeutics Limited
2	Aprica Healthcare Limited (Step-down subsidiary)
3	Eris Oaknet Healthcare Private Limited (Step-down subsidiary)
4	Eris Healthcare Private Limited
5	Eris M. J. Biopharm Private Limited
6	Eris Pharmaceuticals Limited
7	Eris Bionxt Private Limited (Formerly known as Chemman Labs Private Limited)
8	Swiss Parenterals Limited

Joint venture

Sr. No.	Name of entity
1	Levim Lifetech Private Limited





EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Eris Lifesciences Limited

Statement of Unaudited Consolidated Financial results for the quarter and half year ended September 30, 2025

Sr. No.	Particulars	[Rs in Crore except per share data]					
		For quarter ended			For half year ended		
		September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited) (Refer note 9)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited) (Refer note 9)	For year ended March 31, 2025 (Audited)
1	Income						
	Revenue from operations						
	Sale of products	790.15	771.56	738.95	1,561.71	1,454.54	2,879.26
	Other operating income	2.26	1.44	2.22	3.70	6.35	14.38
	Total Revenue from operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
	Other income	2.81	2.69	4.55	5.50	6.19	18.36
	Total income	795.22	775.69	745.72	1,570.91	1,467.08	2,912.00
2	Expenses						
	Cost of materials consumed	82.58	70.10	72.16	152.68	138.63	276.34
	Purchase of stock-in-trade	146.09	104.26	118.35	250.35	243.92	473.12
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(26.26)	10.28	(4.24)	(15.98)	(15.69)	(35.47)
	Employee benefits expense	137.45	144.43	125.63	281.88	258.25	505.09
	Finance costs	49.55	48.68	59.47	98.23	119.84	231.29
	Depreciation and amortisation expense	69.08	70.51	80.38	139.59	156.12	315.46
	Other expenses	164.34	167.22	164.76	331.56	321.28	657.36
	Total expenses	622.83	615.48	616.51	1,238.31	1,222.35	2,423.19
3	Profit before share of profit from investment in joint venture and tax for the period / year (1-2)	172.39	160.21	129.21	332.60	244.73	488.81
4	Share of (profit) from investment in joint venture, net of tax	(0.28)	(0.89)	-	(1.17)	-	(0.06)
5	Profit before tax for the period / year (3-4)	172.67	161.10	129.21	333.77	244.73	488.87
6	Tax Expense						
	Current tax	71.18	56.31	30.25	127.49	55.59	111.84
	Deferred tax	(32.98)	(20.31)	2.55	(53.29)	3.18	2.36
	Total tax expense	38.20	36.00	32.80	74.20	58.77	114.20
7	Net profit for the period / year (5-6)	134.47	125.10	96.41	259.57	185.96	374.67
	Attributable to :						
	- Owners of the Company	120.19	117.99	91.65	238.18	174.96	351.84
	- Non controlling interest	14.28	7.11	4.76	21.39	11.00	22.83
8	Other comprehensive loss						
	Items that will not be reclassified to profit or loss	(0.84)	(0.84)	(0.25)	(1.68)	(1.44)	(3.63)
	Income tax relating to items that will not be reclassified to profit or loss	0.27	0.27	0.09	0.54	0.49	0.34
	Other comprehensive loss for the period / year	(0.57)	(0.57)	(0.16)	(1.14)	(0.95)	(3.29)
	Attributable to :						
	- Owners of the Company	(0.56)	(0.56)	(0.15)	(1.12)	(0.94)	(3.18)
	- Non controlling interest	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	(0.11)
9	Total comprehensive income						
	Attributable to :						
	- Owners of the Company	119.63	117.43	91.50	237.06	174.02	348.66
	- Non controlling interest	14.27	7.10	4.75	21.37	10.99	22.72
	Total comprehensive income for the period / year (7+8)	133.90	124.53	96.25	258.43	185.01	371.38
10	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.62	13.61	13.62	13.61	13.62
11	Other Equity						2,840.74
12	Earnings Per Share (of Rs 1 each) (not annualised) :						
	Basic	8.82	8.66	6.73	17.49	12.84	25.85
	Diluted	8.81	8.64	6.72	17.46	12.82	25.81



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

1. Statement of Consolidated Assets and Liabilities

[Rs in Crore]

Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
I. ASSETS :		
(1) Non Current Assets		
(a) Property, plant and equipment	622.34	604.89
(b) Right-of-use assets	53.76	57.18
(c) Capital work in progress	122.36	66.74
(d) Goodwill	911.97	911.97
(e) Other intangible assets	3,628.76	3,732.44
(f) Intangible assets under development	-	0.27
(g) Investments accounted using equity method	52.66	51.49
(h) Financial assets		
Investments	9.99	10.51
Loans	1.12	1.08
Other financial assets	10.83	10.81
(i) Income tax assets (net)	78.84	39.54
(j) Deferred tax assets (net)	233.63	289.04
(k) Other non-current assets	42.54	34.22
Total Non-current assets	5,768.80	5,810.18
(2) Current assets		
(a) Inventories	408.68	334.83
(b) Financial assets		
Investments	5.00	5.00
Trade receivables	645.42	458.64
Cash and cash equivalents	56.06	199.74
Other bank balances	13.69	23.09
Loans	5.59	5.77
Other financial assets	9.17	3.19
(c) Other current assets	247.55	192.73
Total Current assets	1,391.16	1,222.99
TOTAL- ASSETS	7,159.96	7,033.17
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	13.62	13.62
(b) Other equity	3,077.54	2,840.74
Equity attributable to the owners of the company	3,091.16	2,854.36
(c) Non-controlling interest	412.32	417.40
Total Equity	3,503.48	3,271.76
(2) Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,588.51	1,737.51
Lease liabilities	45.64	44.21
Other financial liabilities	2.31	6.40
(b) Other non-current liabilities	4.12	4.47
(c) Long-term provisions	83.85	68.98
(d) Deferred tax liabilities (net)	409.21	518.45
Total Non-Current liabilities	2,133.64	2,380.02
(3) Current liabilities		
(a) Financial Liabilities		
Borrowings	745.86	684.15
Lease liabilities	8.83	12.05
Trade payables		
i) Due to micro enterprises and small enterprises	17.73	15.98
ii) Due to other than micro enterprises and small enterprises	380.98	316.37
Other financial liabilities	110.45	165.14
(b) Other current liabilities	46.03	66.00
(c) Short-term provisions	51.40	78.09
(d) Income tax liabilities (net)	161.56	43.61
Total Current liabilities	1,522.84	1,381.39
Total liabilities	3,656.48	3,761.41
TOTAL- EQUITY AND LIABILITIES	7,159.96	7,033.17



2. Unaudited Statement of consolidated cash flows for the half year ended September 30, 2025

[Rs in Crore]

Particulars	For the half year ended September 30, 2025 (Unaudited)	For the half year ended September 30, 2024 (Unaudited) (Refer note 9)
A. Cash flow from operating activities		
Profit before tax	333.77	244.73
Adjustments for :		
Depreciation and amortisation expense	139.59	156.12
Net loss on property plant and equipment	0.03	0.03
Finance costs	98.23	119.84
Interest income	(1.44)	(3.15)
Share of profit of an joint venture, net of tax	(1.17)	-
Bad debt written off	-	0.21
Deferred capital subsidy	(0.33)	(0.22)
Net (gain) on sale of investments carried at fair value through profit or loss	(0.68)	(0.71)
Share based payment expense	4.00	4.45
Operating profit before working capital changes	572.00	521.30
Changes in working capital:		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	(186.78)	(38.71)
Inventories	(73.85)	(17.10)
Financial assets	(6.00)	(0.63)
Other assets	(54.77)	57.94
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	66.36	(14.14)
Financial liabilities	4.42	(1.10)
Provisions	(13.50)	20.33
Other liabilities	(19.99)	3.91
Cash generated from operations	287.89	531.80
Net income tax paid	(48.84)	(46.70)
Net cash generated from operating activities (A)	239.05	485.10
B. Cash flow from investing activities		
Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors)	(116.87)	(57.34)
Proceeds from sale of property plant and equipment	0.09	0.08
Consideration paid towards investment in subsidiaries	-	(27.00)
Consideration paid towards business combination	-	(1,142.00)
Investments in mutual funds	-	(36.03)
Proceeds from redemption of mutual funds and fixed deposit	0.68	0.71
Proceeds from redemption of investment in bonds	0.52	-
Investments in compulsory convertible debentures from minority interest in subsidiary	(34.65)	-
Loan given	0.14	(73.93)
Proceeds of bank balances not considered as cash and cash equivalents	9.40	1,249.89
Interest received	1.44	3.18
Net cash used in investing activities (B)	(139.25)	(82.44)
C. Cash flow from financing activities		
Proceeds from borrowings	-	1,400.00
Repayment of borrowings	(87.29)	(1,440.04)
Interest paid	(152.88)	(68.81)
Principal element to lease payment	(6.38)	(4.54)
Proceeds from issue of equity share capital (Employee stock options plan)	3.07	4.04
Payment towards acquisition of the non-controlling interest	-	(237.54)
Net cash used in from financing activities (C)	(243.48)	(346.89)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(143.68)	55.77
Cash and cash equivalents at the beginning of the period	199.74	94.25
Cash and cash equivalents at end of the period	56.06	150.02



3. Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and half year ended September 30, 2025

Particulars	Quarter ended			Half year ended		Year ended
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited) (Refer note 9)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited) (Refer note 9)	March 31, 2025 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.68	0.74	0.86	0.68	0.86	0.76
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.65	2.60	2.15	2.63	2.18	2.24
Interest service coverage ratio (in times) (Earnings before Interest and Tax/Finance Costs)	4.48	4.29	3.17	4.39	3.04	3.11
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	3,503.48	3,399.10	3,177.34	3,503.48	3,177.34	3,271.76
Net profit after tax (Rs in crore)	134.47	125.10	96.41	259.57	185.96	374.67
Earnings per share						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Current Ratio (in times) (Current Assets/Current Liabilities)	0.91	0.93	1.07	0.91	1.07	0.89
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity)	11.36	10.25	6.05	11.36	6.05	14.74
Bad debts to account receivable ratio (in times) (Bad debts/Trade receivables)	Nil	Nil	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.42	0.38	0.32	0.42	0.32	0.37
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.33	0.35	0.39	0.33	0.39	0.35
Debtors' turnover* (in times) (Sales/Trade receivables)	4.63	5.48	5.09	4.63	5.09	6.28
Inventory Turnover Ratio* (in times) (Cost of goods sold/Average Inventory)	2.21	2.41	2.90	2.21	2.90	2.73
Operating margin percent (Earnings before Interest and Tax/Revenue from Operations)	28.01%	27.02%	25.46%	27.52%	24.96%	24.89%
Net profit margin percent (Profit after tax/Revenue from Operations)	16.97%	16.18%	13.01%	16.58%	12.73%	12.95%

*Quarterly ratios based on trailing twelve months values.



Notes to Unaudited Consolidated Financial results

- 4 The above statement of Unaudited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 12, 2025.
- 5 The Unaudited Consolidated Financial results of the Holding Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 6 The Holding Company has issued and allotted 50,985 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the half year ended September 30, 2025. Consequently, the issued and paid-up Share Capital of the Company as on September 30, 2025 stands increased to Rs 13.62 crore.
- 7 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 8 During the previous year ended March 31, 2025, the Holding Company has acquired 1,43,13,418 equity shares representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited), from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction. The Holding Company has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions in the current quarter, consequently there is no material changes in the provisional fair valuation report which was earlier accounted as part of Business Combination.
- 9 During the year ended March 31, 2024, the Holding Company had acquired 51% stake in Swiss Parenterals Limited for a consideration (excluding acquisition expense) of Rs 637.50 crore. The Holding Company has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions in the previous year ended March 31, 2025. Consequent to above the Holding Company has restated the reported amounts of the previous periods as required by the applicable accounting standards.

The summarized position of the reported and restated amounts is as below:

(Rs in crore)

Particulars	Quarter ended September 30, 2024		For the half year ended September 30, 2024	
	Reported	Restated	Reported	Restated
Profit before tax	129.11	129.21	244.43	244.73
Profit after tax	96.35	96.41	185.77	185.96
Total Other Comprehensive Income	96.19	96.25	184.82	185.01

Statement of consolidated cash flows:

(Rs in crore)

Particulars	For the half year ended September 30, 2024	
	Reported	Restated
Net cash generated from operating activities	485.10	485.10
Net cash generated from investing activities	(82.44)	(82.44)
Net cash generated from financing activities	(346.89)	(346.89)


- 10 During the previous year ended March 31, 2025, the Holding Company has sold its equity investment in Eris Oaknet Healthcare Private Limited (EOHPL) and Aprica Healthcare Limited (AHL) to Eris Therapeutics Limited (ETL). As a result, EOHPL and AHL are now a wholly owned subsidiary of ETL.

During the half year ended September 30, 2025, taking into account the revised shareholding structure and other relevant factors arising from the above-mentioned transfer of stake, the ETL proposed the scheme whereby the "Domestic Business" of EOHPL shall get vested into ETL ("Resulting Company/Amalgamated Company") and AHL ("Amalgamating Company") would be amalgamated with ETL.

Accordingly, the respective Boards of Directors of ETL, AHL, and EOHPL have approved the Composite Scheme of Arrangement under Sections 230 to 232, read with Section 66 and other applicable provisions of the Companies Act, 2013. The scheme is subject to necessary statutory and regulatory approvals, as required under applicable laws.



Place: Ahmedabad
Date: November 12, 2025



For Eris Lifesciences Limited,

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Walker ChandioK & Co LLP

Walker ChandioK & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Eris Lifesciences Limited ('the Company') for the quarter ended 30 September 2025 and the year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India



Walker Chandiook & Co LLP


the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 30 September 2024 and audit of standalone financial results for year ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who has expressed unmodified conclusion vide their review report dated 25 October 2024 and unmodified opinion vide their audit report dated 19 May 2025, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013


Ashish Gupta
Partner
Membership No. 504662
UDIN: 25504662BMOOIE4934

Place: Mumbai

Date: 12 November 2025






EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2025

		[Rs. in Crore except per share data]					
Sr. No.	Particulars	For Quarter ended			For Half Year ended		For Year ended
		September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1	Income						
	Revenue from Operations						
	Sale of products	637.58	567.90	428.75	1,205.48	877.92	1,663.63
	Other operating income	12.92	10.74	7.81	23.66	15.33	34.12
	Total Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
	Other Income	23.59	22.68	5.81	46.27	10.97	35.51
	Total Income	674.09	601.32	442.37	1,275.41	904.22	1,733.26
2	Expenses						
	Cost of materials consumed	20.29	24.12	23.19	44.41	47.59	68.35
	Purchase of stock-in-trade	134.83	106.69	112.34	241.52	232.75	474.44
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	42.27	50.71	(10.20)	92.98	(24.49)	(43.54)
	Employee benefits expense	85.42	93.78	89.72	179.20	193.47	361.92
	Finance costs	46.50	45.14	56.26	91.64	112.43	220.24
	Depreciation and amortisation expense	39.30	37.60	46.16	76.90	91.71	181.77
	Other expenses	70.81	87.02	78.88	157.83	177.92	350.03
	Total expenses	439.42	445.06	396.35	884.48	831.38	1,613.21
3	Profit before tax for the period / year (1-2)	234.67	156.26	46.02	390.93	72.84	120.05
4	Tax expense						
	Current tax	40.91	27.17	8.78	68.08	13.47	21.98
	Deferred tax	44.19	29.10	9.14	73.29	14.23	20.68
	Total tax expense	85.10	56.27	17.92	141.37	27.70	42.66
5	Net profit for the period / year (3-4)	149.57	99.99	28.10	249.56	45.14	77.39
6	Other Comprehensive loss						
	Items that will not be reclassified to profit or (loss)	(0.77)	(0.77)	(0.18)	(1.54)	(1.28)	(3.10)
	Income tax relating to items that will not be reclassified to profit or (loss)	0.27	0.27	0.07	0.54	0.45	0.26
	Other Comprehensive loss for the period / year	(0.50)	(0.50)	(0.11)	(1.00)	(0.83)	(2.84)
7	Total Comprehensive Income for the period / year (5+6)	149.07	99.49	27.99	248.56	44.31	74.55
8	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.62	13.61	13.62	13.61	13.62
9	Other Equity						2,501.28
10	Earnings Per Share (of Rs 1 each) (not annualised) :						
	Basic	10.98	7.34	2.06	18.32	3.32	5.69
	Diluted	10.96	7.33	2.06	18.29	3.31	5.68




Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

1. Statement of Standalone Assets and Liabilities

[Rs in Crore]

Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
I. ASSETS :		
(1) Non-current assets		
(a) Property, plant and equipment	78.23	74.70
(b) Right-of-use asset	28.15	32.47
(c) Goodwill	48.57	48.57
(d) Other intangible assets	2,197.39	2,256.44
(e) Intangible assets under development	-	0.27
(f) Financial assets		
Investments	990.76	991.27
Loans	306.85	249.11
Other financial assets	429.55	639.06
(g) Income tax assets (net)	38.20	12.64
(h) Deferred tax assets (net)	210.61	283.36
(i) Other non-current assets	9.89	7.00
Total Non-current assets	4,338.20	4,594.89
(2) Current assets		
(a) Inventories	98.40	191.25
(b) Financial assets		
Trade receivables	670.50	236.19
Cash and cash equivalents	10.42	84.34
Other bank balances	2.85	8.12
Loans	227.09	14.01
Other financial assets	42.50	7.20
(c) Other current assets	46.96	86.43
Total Current assets	1,098.72	627.54
TOTAL- ASSETS	5,436.92	5,222.43
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Equity share capital	13.62	13.62
(b) Other equity	2,756.95	2,501.28
Total equity	2,770.57	2,514.90
(2) Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,515.51	1,632.64
Lease liabilities	22.71	22.01
(b) Other non-current liabilities	0.71	0.96
(c) Long term provisions	29.29	57.98
Total Non-current liabilities	1,568.22	1,713.59
(3) Current liabilities		
(a) Financial Liabilities		
Borrowings	645.29	580.31
Lease liabilities	5.71	9.91
Trade payables		
i) Due to micro enterprises and small enterprises	5.28	3.06
ii) Due to other than micro enterprises and small enterprises	244.89	213.02
Other financial liabilities	75.10	126.77
(b) Other current liabilities	11.29	15.95
(c) Short term provisions	36.83	39.26
(d) Income tax liabilities (net)	73.74	5.66
Total Current liabilities	1,098.13	993.94
Total liabilities	2,666.35	2,707.53
TOTAL- EQUITY AND LIABILITIES	5,436.92	5,222.43



2. Unaudited Statement of standalone cash flows for the half year ended September 30, 2025

[Rs in Crore]

Particulars	For the half year ended	
	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)
A. Cash flow from operating activities		
Profit before tax	390.93	72.84
Adjustments for :		
Depreciation and amortisation expense	76.90	91.71
Net Loss on property plant and equipment	0.03	0.03
Finance costs	91.64	112.43
Interest income	(35.88)	(3.18)
Deferred capital subsidy	(0.23)	(0.22)
Net (gain) on sale of investments carried at fair value through profit or loss	(0.68)	(0.71)
Share based payment expense	4.00	4.45
Operating profit before working capital changes	526.71	277.35
Changes in working capital:		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	(434.31)	34.51
Inventories	92.85	(14.57)
Financial assets	(0.31)	(1.01)
Other assets	39.52	65.19
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	34.09	(32.83)
Financial liabilities	0.73	(0.86)
Provisions	(32.66)	26.09
Other liabilities	(4.68)	1.52
Cash generated from operations	221.94	355.39
Net income tax paid	(25.55)	(10.24)
Net cash flow from operating activities (A)	196.39	345.15
B. Cash flow from investing activities		
Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors)	(22.37)	(7.26)
Proceeds from sale of property plant and equipment	0.09	(0.05)
Consideration paid towards business combination	-	(1,142.00)
Consideration paid towards investment in subsidiaries	-	(264.53)
Proceeds from redemption of mutual funds	0.68	0.71
Proceeds from subsidiary on account of sale of investments	209.75	-
Proceeds from redemption of investment in bonds	0.51	-
Loan given to subsidiaries	(285.20)	(89.75)
Loan repaid by subsidiaries	14.50	7.50
Loan given to others	-	0.04
Loan given to others received back	(0.12)	-
Investments in mutual funds and fixed deposit	5.27	-
Proceeds of Bank balances not considered as cash and cash equivalents	-	1,237.57
Interest income	0.68	3.19
Net cash used in investing activities (B)	(76.21)	(254.58)
C. Cash flow from financing activities		
Proceeds from borrowings	-	1,400.00
Repayment of borrowings	(50.33)	(1,427.56)
Proceeds of borrowings from subsidiaries	9.10	92.35
Repayment of borrowings to subsidiaries	(10.92)	(54.19)
Interest paid	(141.20)	(61.85)
Principal element to lease payment	(3.82)	(4.11)
Proceeds from issue of equity share capital (employee stock options plan)	3.07	4.04
Net cash flow used in financing activities (C)	(194.10)	(51.32)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(73.92)	39.25
Cash and cash equivalents at the beginning of the period	84.34	51.93
Cash and cash equivalents at end of the period	10.42	91.18



3. Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and half year ended September 30, 2025

Particulars	Quarter ended			Half Year ended		Year ended
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.79	0.89	1.00	0.79	1.00	0.89
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.61	2.14	1.52	2.38	1.51	1.48
Interest service coverage ratio (in times) (Earnings before Interest and Tax/Finance Costs)	6.05	4.46	1.82	5.27	1.65	1.55
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	2,770.57	2,618.51	2,576.86	2,770.57	2,576.86	2,514.90
Net profit after tax (Rs in crore)	149.57	99.99	28.10	249.56	45.14	77.39
Earnings per share						
Basic	10.98	7.34	2.06	18.32	3.32	5.69
Diluted	10.96	7.33	2.06	18.29	3.31	5.68
Current Ratio (in times) (Current Assets/Current Liabilities)	1.00	0.81	0.73	1.00	0.73	0.63
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity))	7.52	64.47	(32.79)	7.52	(32.79)	(14.23)
Bad debts to account receivable ratio (in times) (Bad debts/ Trade receivables)	Nil	Nil	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.41	0.39	0.37	0.41	0.37	0.37
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.40	0.44	0.47	0.40	0.47	0.43
Debtors' turnover* (in times) (Sales/ Trade receivables)	2.97	3.74	6.55	2.97	6.55	7.04
Inventory Turnover Ratio* (in times) (Cost of goods sold/Average Inventory)	4.89	3.34	3.19	4.89	3.19	3.53
Operating margin percent (Earnings before Interest and Tax/Revenue from Operations)	43.22%	34.81%	23.43%	39.26%	20.74%	20.04%
Net profit margin percent (Profit after tax/Revenue from Operations)	22.99%	17.28%	6.44%	20.30%	5.05%	4.56%

*Quarterly ratios based on trailing twelve months values.



Notes to Unaudited Standalone Financial results


- 4 The above statement of Unaudited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 12, 2025.
- 5 The Unaudited Standalone Financial results of the Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 6 The Company has issued and allotted 50,985 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the half year ended September 30, 2025. Consequently, the issued and paid-up Share Capital of the Company as on September 30, 2025 stands increased to Rs 13.62 crore.
- 7 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".

For Eris Lifesciences Limited,



Place: Ahmedabad

Date: November 12, 2025



A handwritten signature in black ink, appearing to read "Amit Bakshi".

Amit Bakshi

Chairman and Managing Director

DIN : 01250925



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Annexure 1

Re-appointment of Mr. Krishnakumar Vaidyanathan as Whole Time Director of the Company:	
Reason for change:	Re-appointment
Date of Re-appointment:	September 01, 2026
Term of Re-appointment:	5 Years
Brief Profile:	Not Applicable
Disclosure of relationships between directors:	Not Applicable

Re-appointment of Ms. Kalpana Unadkat as an Independent Director of the Company:	
Reason for change:	Re-appointment
Date of Re-appointment:	January 05, 2026
Term of Re-appointment:	5 Years
Brief Profile:	Not Applicable
Disclosure of relationships between directors:	Not Applicable

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867